Recent Quotes (30 days)

You have no recent quotes
chg | %

Maxygen, Inc.  

(Public, NASDAQ:MAXY)   Watch this stock  
Find more results for MAXY
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield 2.50
EPS -0.35
Shares 27.79M
Beta     -
Inst. own 59%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin - 68.55%
Operating margin - 67.51%
EBITD margin - 67.69%
Return on average assets -15.91% 16.60%
Return on average equity -16.57% 16.70%
Employees 6 -
CDP Score - -


Suite 616, 411 Borel Avenue
United States - Map
+1-650-2412292 (Phone)
+1-650-2575892 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company�s interests in Perseid Therapeutics LLC, the Company�s former subsidiary, which included all of the Company�s research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company�s wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.